LifeArc's Ducentis BioTherapeutics Agrees To Be Acquired By Arcutis For Up To $400 Mln

(RTTNews) - LifeArc said that its portfolio company DucentisBioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases, agreed to be acquired by ArcutisBiotherapeutics Inc. (ARQT). The Agreement values Ducentis at up to $400 million, including upfront cash payment of $16 million and Arcutis stock valued at about $14 million, plus future contingent payments based on development and commercial success.

Ducentis' lead pre-clinical asset, DS-234, is being developed for the treatment of atopic dermatitis, a rapidly growing, significantly underserved market.

Closing of the transaction will be subject to customary closing conditions.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.